Metabolic Syndrome

MINGHAN “MING” WANG, PHD is Director and head of a metabolism group in Metabolic Disorders Research at Amgen. He has authored over forty publications and is a regular speaker at drug discovery conferences.

• Introduction ixMinghan WangContributors xiPart One The Physiology of Metabolic Tissues Under Normal and Disease States1. Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism 3Minghan Wang2. Central Glucose Sensing and Control of Food Intake and Energy Homeostasis 29Lourdes Mounien and Bernard Thorens3. Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus 53Taly Meas and Pierre-Jean Guillausseau4. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae 73Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter Zahradka5. Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis 133Ruojing Yang6. Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance 157Minghan WangPart Two Metabolic Diseases and Current Therapies7. Mechanisms and Complications of Metabolic Syndrome 179Minghan Wang8. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL 199Margrit Schwarz and Jae B. Kim9. Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery 235Devan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap10. Current Antidiabetic Therapies and Mechanisms 253Minghan WangPart Three Drug Targets for Antidiabetic Therapies11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies 281Remy Burcelin, Cendrine Cabou, Christophe Magnan, and Pierre Gourdy12. Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes 327C.H.S. McIntosh, S.-J. Kim, R.A. Pederson, U. Heiser, and H.-U. Demuth13. Sodium Glucose Cotransporter 2 Inhibitors 359Margaret Ryan and Serge A. Jabbour14. Fibroblast Growth Factor 21 as a Novel Metabolic Regulator 377Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov15. Sirtuins as Potential Drug Targets for Metabolic Diseases 391Qiang Tong16. 11β-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes 423Clarence Hale and David J. St. Jean, Jr.17. Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade 459Hai Yan, Wei Gu, and Murielle Veniant-EllisonPart Four Lessons Learned and Future Outlook18. Drug Development for Metabolic Diseases: Past, Present and Future 471Minghan WangIndex 489

"This is an outstanding addition to the current body of work on the metabolic syndrome. I thought it particularly exhaustive in its review of the literature, making it an excellent resource for scouring the primary literature, and found the duality of current and future treatment approaches particularly insightful." (Doody's, 21 October 2011) "The book offers a comprehensive and in-depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism-based drug discovery and clinical implications." (Pharmiweb, 1 March 2011)